A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still, the recognition of symptom patterns…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for multiple…
Multiple myeloma patients taking the immunomodulatory drug thalidomide may develop a potentially life-threatening dermatologic disorder called toxic epidermal necrolysis (TEN), according to a recent case…
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according…
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple…
The anti-CD38 agent Darzalex (daratumumab) will be investigated in a Phase 3 clinical trial in combination with Kyprolis (carfilzomib) and Decadron (dexamethasone) in relapsed/refractory multiple…
The U.S. Food and Drug Administration (FDA) has verbally notified BioInvent International that it’s placing a full clinical hold on the company’s Phase 2 trial evaluating…
Karyopharm Therapeutics is set to present novel clinical data on its lead product candidate selinexor, an oral selective inhibitor of nuclear export compound that…
MorphoSys, the creator of HuCAL (Human Combinatorial Antibody Library), will give two oral and one poster presentation on the company’s proprietary antibody hemato-oncological programs, MOR208 and…
Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the upcoming 58th American Society…